External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<div><div><div><ul style="list-style-type: disc;"><li><p>The FDA review for 510(k) applications takes between 3 and 9 months, so we expect an FDA decision between December 2023 and June 2024.</p></li><li><p>GSS has not disclosed the results of the 1,500 patient US trial, but the significant investment it is making in preparation for a US commercial launch indicates that it is confident in the quality of the data package it has submitted.</p></li><li><p>With the kit already approved in Australia, Europe and Canada, we believe that there as a high probability of a positive FDA decision.</p></li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

The FDA review for 510(k) applications takes between 3 and 9 months, so we expect an FDA decision between December 2023 and June 2024.GSS has not disclosed the results of the 1,500 patient US trial, but the significant investment it is making in preparation for a US commercial launch indicates that it is confident in the quality of the data package it has submitted.With the kit already approved in Australia, Europe and Canada, we believe that there as a high probability of a positive FDA decision.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Genetic Signatures (GSS) - Preparing for Potential US Launch H2 FY24